COVID-19 therapy: VibioSphen and the IPBS join forces to explore the potential of novel drugs
VibioSphen and the IPBS share common goals in the fight against infectious diseases. Today, both institutions decided to join forces through a partnership in order to accelerate the development of new treatments for COVID-19.
Shortly after the start of the pandemic, the IPBS decided to adapt and equip its biosafety level 3 (BSL3) facilities, normally dedicated to the study of respiratory pathogens such as the tuberculosis bacillus, to be able to carry out experiments on the new SARS-CoV-2 virus. Thanks to the efforts of IPBS scientists Céline Berrone and Céline Cougoule, this capacity is now available to the private and public scientific communities through the Anexplo and TRI facilities, members of the Toulouse Genopole consortium Genotoul.
“This partnership is a unique opportunity for our institute to directly participate in the development of novel and promising therapeutics against COVID-19”, said Jean-Philippe Girard, Director of IPBS.
“VibioSphen constantly seeks partnerships to have early access to transformative innovation. We believe that the BSL3 facilities of IPBS, and the expertise of the IPBS scientists in respiratory infectious diseases can make a difference in the preclinical studies of our drug candidates”, said Maxime Fontanié, Chief Executive Officer at VibioSphen.
IPBS contact persons
Mrs. Céline Berrone, BSL3 facility manager I firstname.lastname@example.org
Dr. Céline Cougoule, IPBS contact person for COVID-19-related projects I email@example.com
Dr. Magali Jacquier, Head of the Anexplo-IPBS core facility I firstname.lastname@example.org
Dr. Antonio Peixoto, Head of the TRI-IPBS Imaging core facility I email@example.com
©CDC/SCIENCE PHOTO LIBRARY